APH1A Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APH1A Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>APH1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>APH1A</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=APH1" target="_blank">Search NCBI</a></td>
</tr>
</table>
Aph1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-gene [@sannerud2016]
Symbol: APH1A [@serneels2005]
Full Name: Anterior Pharynx Defective 1 Homolog A [@acx2014]
Chromosomal Location: 1p36.33-p36.32 [@wolfe2017]
NCBI Gene ID: [116511](https://www.ncbi.nlm.nih.gov/gene/116511) [@haass2012]
OMIM: [607630](https://www.omim.org/entry/607630) [@pettersen2015]
Ensembl ID: [ENSG00000144024](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144024) [@takeo2016]
UniProt: [Q9WFF5](https://www.uniprot.org/uniprot/Q9WFF5)
Proteins: [APH1A](/proteins/aph1a)
Associated Diseases: [Alzheimer's Disease](/diseases/alzheimers-disease)
::
Overview
...APH1A Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APH1A Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>APH1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>APH1A</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=APH1" target="_blank">Search NCBI</a></td>
</tr>
</table>
Aph1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-gene [@sannerud2016]
Symbol: APH1A [@serneels2005]
Full Name: Anterior Pharynx Defective 1 Homolog A [@acx2014]
Chromosomal Location: 1p36.33-p36.32 [@wolfe2017]
NCBI Gene ID: [116511](https://www.ncbi.nlm.nih.gov/gene/116511) [@haass2012]
OMIM: [607630](https://www.omim.org/entry/607630) [@pettersen2015]
Ensembl ID: [ENSG00000144024](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144024) [@takeo2016]
UniProt: [Q9WFF5](https://www.uniprot.org/uniprot/Q9WFF5)
Proteins: [APH1A](/proteins/aph1a)
Associated Diseases: [Alzheimer's Disease](/diseases/alzheimers-disease)
::
Overview
Mermaid diagram (expand to render)
APH1A (Anterior Pharynx Defective 1 Homolog A) encodes a critical component of the [gamma-secretase](/entities/gamma-secretase) complex, one of the most important enzymatic complexes in [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis. APH1A is expressed ubiquitously but shows particularly high expression in the brain, especially in regions vulnerable to AD pathology like the [hippocampus](/brain-regions/hippocampus) and cerebral [cortex](/brain-regions/cortex). The gamma-secretase complex, which includes APH1A, presenilin ([PSEN1](/entities/psen1)/PSEN2), nicastrin, and PEN-2, is responsible for the proteolytic cleavage of [amyloid precursor protein](/entities/app-protein) (APP) to generate [amyloid-beta](/proteins/amyloid-beta) (Abeta) peptides. The specific composition of the gamma-secretase complex, determined in part by which APH1 isoform is incorporated, directly influences the Abeta peptide profile produced.
Gamma-Secretase Complex Assembly
Complex Composition
The gamma-secretase complex is a heterotetrameric aspartyl protease:
Presenilin (PSEN1 or PSEN2): The catalytic subunit containing two aspartyl protease active sites
Nicastrin (NCT): Acts as a substrate receptor, recognizing the extracellular domain of APP
PEN-2 (PSENEN): Essential for presenilin endoproteolysis and stabilization
APH1A or APH1B: Scaffold protein that organizes the complex in the endoplasmic reticulumMammalian cells express two APH1 genes with multiple isoforms:
- APH1A: Two isoforms (APH1A-L, APH1A-S) produced by alternative splicing
- APH1B/APH1C: Additional isoforms with tissue-specific expression
The different APH1 isoforms confer distinct properties to gamma-secretase:
- Substrate preference differences
- Endoplasmic reticulum localization
- Assembly kinetics
- Aβ product profiles (Aβ40 vs Aβ42 ratio)
Molecular Function
Catalytic Activity
Gamma-secretase performs regulated intramembrane proteolysis (RIP):
First cleavage (ε-site): Initial APP cleavage within the transmembrane domain
Second cleavage (γ-site): Successive cleavages releasing Aβ peptides of varying lengthsThe Aβ40/Aβ42 ratio produced depends on gamma-secretase composition:
- APH1A-containing complexes tend to produce more Aβ40
- Certain PSEN1 mutations shift toward Aβ42 production
Substrate Diversity
Gamma-secretase cleaves over 100 type I transmembrane substrates:
- Amyloid Precursor Protein (APP)
- Notch receptors
- E-cadherin
- N-cadherin
- LDL receptor-related proteins
- ErbB4
- DCC
This broad substrate range explains the complex biology and side effects of gamma-secretase inhibitors.
Expression Pattern
Brain Expression
- [Neurons](/entities/neurons): High expression in pyramidal neurons of cortex and hippocampus
- Glia: Moderate expression in [astrocytes](/entities/astrocytes)
- Regional variation: Highest in [entorhinal cortex](/brain-regions/entorhinal-cortex), CA1 hippocampus, basal forebrain
Peripheral Expression
- Heart, liver, kidney, lung
- Lymphocytes
- Pancreatic islets
Disease Associations
Alzheimer's Disease
APH1A is centrally involved in AD pathogenesis:
Amyloid-beta production: APH1A-containing gamma-secretase generates Aβ from APP
Genetic variants: Certain APH1A polymorphisms may influence AD risk
Presenilin partnerships: APH1A coordinates with PSEN1/PSEN2 mutations
Therapeutic target: Modulating APH1A-gamma-secretase to reduce toxic Aβ42Alzheimer's Disease Therapeutics
Gamma-secretase modulators (GSMs): Compounds that shift cleavage toward shorter, less aggregation-prone Aβ peptides
APH1A-targeted approaches: Developing drugs that selectively inhibit APP cleavage while sparing Notch
Allosteric modulators: Targeting APH1A-NCT interface to allosterically modulate activitySide Effect Considerations
Because gamma-secretase also cleaves Notch:
- Complete inhibition causes gastrointestinal toxicity
- Partial inhibition or modulation preferred over complete blockade
- APH1 isoform-selective modulation is an active research area
Therapeutic Implications
Drug Development Strategies
Selective GSMs: Preferentially promote non-amyloidogenic APP processing
Notch-sparing inhibitors: Target APP cleavage while preserving Notch signaling
Antibody-based approaches: Target APH1A or gamma-secretase complex assemblyChallenges
- Broad substrate specificity of gamma-secretase
- Mechanism-based toxicity from Notch inhibition
- Need for brain-penetrant compounds
- [Gamma-Secretase Complex](/proteins/gamma-secretase)
- [APP Processing](/mechanisms/app-processing)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [APH1A Protein](/proteins/aph1a)
- [Gene index](/genes)
- [--](/proteins/n--cadherin-protein)
Background
The study of Aph1A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[De Strooper B, "Loss-of-function presenilin mutations in Alzheimer disease." EMBO Journal (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/29251994/)
[Sannerud R, Esselens C, Ejsmont P, et al, "Restricted location of PSEN2/γ-secretase determines substrate specificity and cellular effects of γ-secretase modulators." EMBO Journal (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27294251/)
[Serneels L, Dejaegere T, Craessaerts K, et al, "Differential contribution of the three presenilin genes to the γ-secretase complex in vivo." Proceedings of the National Academy of Sciences (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15677324/)
[Acx H, Chávez-Gutiérrez L, Serneels L, et al, "Signature amyloid β profiles are produced by different γ-secretase complexes." Journal of Biological Chemistry (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24895120/)
[Wolfe MS, " γ-Secretase inhibition and modulation for Alzheimer's disease." Current Alzheimer Research (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28093938/)
[Haass C, Kaether C, Thinakaran G, et al, "Trafficking and proteolytic processing of APP." Cold Spring Harbor Perspectives in Medicine (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22553493/)
[Pettersen M, Iyer G, Srivastava A, et al, "APH1B and APH1C polymorphisms and Alzheimer disease risk." Neurobiology of Aging (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25697672/)
[Takeo K, Tanimura S, Allin O, et al, "ATP1A3 mutations cause focal epilepsy." Brain (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26962052/)Pathway Diagram
The following diagram shows the key molecular relationships involving APH1A Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)